Academic Journal
Προβολή σε EDS

Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece.
Συγγραφείς: Tzanetakos C; Health Through Evidence, Athens, Greece., Vakouftsi VR; Hellenic Society of Crohn's disease's and Ulcerative Colitis' patients (HELLESCC), Athens, Greece., Mavridoglou G; University of Peloponnese, Kalamata, Greece., Angelopoulou A; Health Through Evidence, Athens, Greece., Gourzoulidis G; Health Through Evidence, Athens, Greece.
Πηγή: Frontiers in immunology [Front Immunol] 2026 Jul 10; Vol. 17, pp. 1866461. Date of Electronic Publication: 2026 Jul 10 (Print Publication: 2026).
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Imprint Name(s): Original Publication: [Lausanne : Frontiers Research Foundation]
Ιατρικοί όροι (MeSH): Inflammatory Bowel Diseases*/epidemiology , Inflammatory Bowel Diseases*/therapy , Crohn Disease*/epidemiology , Crohn Disease*/therapy , Colitis, Ulcerative*/epidemiology , Colitis, Ulcerative*/therapy , Cost of Illness*, Greece/epidemiology ; Humans ; Male ; Female ; Adult ; Middle Aged ; Patient Reported Outcome Measures ; Quality of Life ; Aged ; Severity of Illness Index ; Surveys and Questionnaires ; Symptom Burden
Περίληψη: Objectives: Despite therapeutic advances, inflammatory bowel disease (IBD) remains a lifelong debilitating disorder with substantial burden. The study aimed to investigate disease burden and unmet needs in IBD patients receiving advanced therapies in Greece.
Methods: Between October 2023 and January 2024, adult CD and UC patients who were members of Hellenic Society of Crohn's disease's and Ulcerative Colitis' patients (HELLESCC) and receiving advanced therapies completed a structured self-reported questionnaire. The survey collected data on sociodemographic characteristics, smoking status, comorbidities, disease activity, disease characteristics, current medications, and patient-reported outcomes (PROs; Short Inflammatory Bowel Disease Questionnaire [SIBDQ], Work Productivity and Activity Impairment [WPAI], Patient Health Questionnaire-9 [PHQ-9], treatment satisfaction and adherence). Both univariate and multivariate logistic regression analyses were performed to determine associated factors.
Results: Among 287 patients with IBD (201 with CD, 86 with UC) receiving advanced therapies, 57.1% had active disease. Overall, 76.4% reported impaired QoL, 30.3% work productivity loss, and 38.4% activity impairment, while nearly half exhibited moderate-to-severe depressive symptoms. Notably, 39.1% expressed dissatisfaction with their advanced therapy, while 10.9% reported reduced adherence. No significant differences were observed between CD and UC patients across PROs, except for adherence. Higher disease activity was consistently associated with worse QoL, greater work impairment, increased depressive symptoms, and lower treatment satisfaction.
Conclusion: Despite advanced therapies, IBD burden remains substantial among Greek patients. A considerable proportion experience poor QoL, increased work impairment, significant depressive symptoms, and persistent disease activity. Marked treatment dissatisfaction, reported by four out of ten patients, highlights an unmet need for more effective management strategies.
(Copyright © 2026 Tzanetakos, Vakouftsi, Mavridoglou, Angelopoulou and Gourzoulidis.)
Competing Interests: Author V-RV is the president of HELLESCC. Authors GG and CT are owners of Health Through Evidence. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References: Clin Gastroenterol Hepatol. 2014 Aug;12(8):1246-56.e6. (PMID: 24534550)
Can J Gastroenterol Hepatol. 2017;2017:6496727. (PMID: 29181373)
Can J Gastroenterol Hepatol. 2017;2017:6138105. (PMID: 28634576)
Gut. 1998 Jul;43(1):29-32. (PMID: 9771402)
Life (Basel). 2023 Aug 05;13(8):. (PMID: 37629549)
J Crohns Colitis. 2017 Feb;11(2):165-174. (PMID: 27516406)
Med Sci (Basel). 2025 Aug 08;13(3):. (PMID: 40843739)
Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):717-726. (PMID: 35732730)
Ther Adv Gastroenterol. 2025 Mar 30;18:17562848251325190. (PMID: 40166589)
J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941)
World J Gastroenterol. 2019 Oct 14;25(38):5862-5882. (PMID: 31636478)
Int J Clin Pharm. 2026 Feb;48(1):51-66. (PMID: 41369787)
Gut Liver. 2022 Mar 15;16(2):157-170. (PMID: 34456186)
Int J Environ Res Public Health. 2023 Jun 29;20(13):. (PMID: 37444101)
J Crohns Colitis. 2024 Sep 3;18(9):1486-1504. (PMID: 38647194)
J Crohns Colitis. 2015 Oct;9(10):819-29. (PMID: 26116554)
Aliment Pharmacol Ther. 2022 Aug;56(4):664-674. (PMID: 35633043)
Drugs. 2023 Jul;83(10):909-921. (PMID: 37219801)
Curr Opin Pharmacol. 2025 Dec;85:102577. (PMID: 41124980)
United European Gastroenterol J. 2019 Aug;7(7):942-954. (PMID: 31428419)
Lancet. 2022 Jun 4;399(10341):2113-2128. (PMID: 35644166)
Crohns Colitis 360. 2024 Nov 29;7(1):otae074. (PMID: 39834357)
Inflamm Bowel Dis. 2019 Jul 17;25(8):1417-1427. (PMID: 30839057)
Dis Mon. 2024 Jan;70(1S):101672. (PMID: 38143196)
Front Immunol. 2021 Mar 18;12:614653. (PMID: 33815372)
Dtsch Arztebl Int. 2009 May;106(19):335-9. (PMID: 19547734)
Cureus. 2025 Nov 19;17(11):e97297. (PMID: 41426881)
Health Qual Life Outcomes. 2017 Sep 15;15(1):177. (PMID: 28915891)
Curr Rev Musculoskelet Med. 2011 Sep;4(3):123-31. (PMID: 21710141)
Scand J Gastroenterol. 2003 Feb;38(2):164-71. (PMID: 12678333)
J Clin Med. 2019 Aug 05;8(8):. (PMID: 31387259)
Am J Gastroenterol. 1996 Aug;91(8):1571-8. (PMID: 8759664)
BMC Gastroenterol. 2022 Nov 26;22(1):487. (PMID: 36435785)
Rev Esp Enferm Dig. 2017 Aug;109(8):542-551. (PMID: 28679280)
Dis Mon. 2019 Dec;65(12):100851. (PMID: 30837080)
Ann Gastroenterol. 2022 May-Jun;35(3):267-274. (PMID: 35599924)
Cureus. 2022 Aug 28;14(8):e28502. (PMID: 36185946)
Lancet. 2023 Apr 8;401(10383):1159-1171. (PMID: 36871574)
Medicina (Kaunas). 2023 Mar 30;59(4):. (PMID: 37109640)
J Can Assoc Gastroenterol. 2020 May 16;4(2):91-96. (PMID: 33855267)
J Crohns Colitis. 2022 Aug 4;16(7):1030-1038. (PMID: 35102373)
Crohns Colitis 360. 2023 Feb 22;5(2):otad006. (PMID: 36937140)
Medicina (Kaunas). 2025 Aug 23;61(9):. (PMID: 41010903)
J Crohns Colitis. 2014 Apr;8(4):318-25. (PMID: 24120021)
Ann Gastroenterol. 2025 Nov-Dec;38(6):629-640. (PMID: 41586393)
Intern Med J. 2018 Oct;48(10):1234-1241. (PMID: 29663629)
Pharmacoeconomics. 1993 Nov;4(5):353-65. (PMID: 10146874)
Crohns Colitis 360. 2022 Jun 15;4(3):otac023. (PMID: 36777416)
Ann Gastroenterol. 2013;26(1):52-58. (PMID: 24714294)
Inflamm Bowel Dis. 2006 Apr;12(4):304-10. (PMID: 16633052)
Intest Res. 2021 Jan;19(1):45-52. (PMID: 32093437)
Health Qual Life Outcomes. 2020 Jul 20;18(1):241. (PMID: 32690091)
Adv Ther. 2023 Oct;40(10):4321-4338. (PMID: 37458875)
Gastro Hep Adv. 2022 Jul 19;1(6):927-935. (PMID: 39131245)
United European Gastroenterol J. 2025 Apr;13(3):364-375. (PMID: 39425758)
Arch Public Health. 2025 Jun 13;83(1):151. (PMID: 40514703)
Contributed Indexing: Keywords: Crohn’s disease; advanced therapies; disease burden; patient-reported outcomes; ulcerative colitis; unmet medical needs
Entry Date(s): Date Created: 20260725 Date Completed: 20260725 Latest Revision: 20260813
Update Code: 20260814
PubMed Central ID: PMC13396155
DOI: 10.3389/fimmu.2026.1866461
PMID: 42500675
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1664-3224
DOI:10.3389/fimmu.2026.1866461